Institute of Biomedical Research Corp. (MRES)
USD 0.01
(5.38%)
USD 0.01
(5.38%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2010 | -261.72 Thousand USD | 38.68% |
| 2009 | -426.79 Thousand USD | 92.05% |
| 2008 | -5.36 Million USD | -554.95% |
| 2007 | -819.48 Thousand USD | -512.69% |
| 2006 | -133.75 Thousand USD | 0.0% |
| 2004 | -14.33 Thousand USD | -29.14% |
| 2003 | -11.1 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2010 Q2 | -50.06 Million USD | -43219.64% |
| 2010 Q3 | -35.95 Thousand USD | 99.93% |
| 2010 Q4 | -18.11 Thousand USD | 49.62% |
| 2010 Q1 | -115.57 Thousand USD | -17.46% |
| 2010 FY | -261.72 Thousand USD | 38.68% |
| 2009 Q2 | -31.6 Thousand USD | 78.69% |
| 2009 FY | -426.79 Thousand USD | 92.05% |
| 2009 Q3 | -21.18 Thousand USD | 32.97% |
| 2009 Q1 | -148.31 Thousand USD | -73.91% |
| 2009 Q4 | -98.39 Thousand USD | -364.51% |
| 2008 Q1 | -4.74 Million USD | -2615.14% |
| 2008 Q4 | -85.28 Thousand USD | 10.28% |
| 2008 Q3 | -95.05 Thousand USD | 7.85% |
| 2008 Q2 | -103.14 Thousand USD | 97.83% |
| 2008 FY | -5.36 Million USD | -554.95% |
| 2007 Q2 | -147.68 Thousand USD | 81.48% |
| 2007 FY | -819.48 Thousand USD | -512.69% |
| 2007 Q4 | -174.72 Thousand USD | 41.44% |
| 2007 Q3 | -298.37 Thousand USD | -102.04% |
| 2007 Q1 | -797.34 Thousand USD | -19486.05% |
| 2006 FY | -133.75 Thousand USD | 0.0% |
| 2006 Q4 | -4071.00 USD | 72.72% |
| 2006 Q3 | -14.92 Thousand USD | -281.59% |
| 2006 Q2 | -3911.00 USD | -103.28% |
| 2006 Q1 | 119.37 Thousand USD | 205.13% |
| 2005 Q3 | -136.82 Thousand USD | -2248.96% |
| 2005 Q4 | -113.55 Thousand USD | 17.01% |
| 2005 Q2 | -5825.00 USD | -381.8% |
| 2005 Q1 | -1209.00 USD | 32.31% |
| 2004 Q3 | -1042.00 USD | 85.5% |
| 2004 Q2 | -7188.00 USD | -91.99% |
| 2004 FY | -14.33 Thousand USD | -29.14% |
| 2004 Q4 | -1786.00 USD | -71.4% |
| 2004 Q1 | -3744.00 USD | 0.0% |
| 2003 FY | -11.1 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 80.401% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 94.812% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 98.534% |
| Nascent Biotech, Inc. | -2.22 Million USD | 88.263% |
| Rebus Holdings, Inc. | -664 Thousand USD | 60.583% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.32% |
| Qrons Inc. | -643.67 Thousand USD | 59.339% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 32.817% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 99.528% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 37.006% |
| Skye Bioscience, Inc. | -13.67 Million USD | 98.086% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.635% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 105.325% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.655% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 90.818% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 82.961% |
| Mesoblast Limited | -84.14 Million USD | 99.689% |
| Marizyme, Inc. | -34.08 Million USD | 99.232% |
| Genus plc | 6.4 Million USD | 104.089% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 102.686% |
| Pharming Group N.V. | -4.87 Million USD | 94.636% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 86.825% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 71.899% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 96.866% |
| ContraFect Corporation | -56.88 Million USD | 99.54% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 94.254% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 81.332% |
| IMV Inc. | -38.67 Million USD | 99.323% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 90.486% |
| MultiCell Technologies, Inc. | -722.81 USD | -36109.516% |
| ONE Bio Corp. | 13.68 Million USD | 101.913% |
| Accustem Sciences Inc. | -3.74 Million USD | 93.014% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 99.556% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 45.819% |
| Q BioMed Inc. | -3.44 Million USD | 92.404% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 107.393% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 90.039% |
| Biomind Labs Inc. | -1 Million USD | 74.076% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 99.524% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 90.979% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 96.063% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 85.962% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -773.818% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 98.351% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 86.457% |
| GB Sciences, Inc. | -1.42 Million USD | 81.575% |
| Alpha Cognition Inc. | -9.7 Million USD | 97.303% |
| HST Global, Inc. | -140.9 Thousand USD | -85.744% |
| CSL Limited | 3.7 Billion USD | 100.007% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 76.734% |
| Halberd Corporation | -75.05 Thousand USD | -248.736% |
| Enzolytics Inc. | -2.14 Million USD | 87.82% |
| Agentix Corp. | -1.37 Million USD | 80.92% |
| Resverlogix Corp. | -12.74 Million USD | 97.947% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 91.739% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.938% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 74.93% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 91.035% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 83.428% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 92.313% |
| AVAX Technologies, Inc. | 6.69 Million USD | 103.911% |
| Zenith Capital Corp. | -8.94 Million USD | 97.073% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.937% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -1402.359% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 89.34% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -52.601% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 86.945% |
| Kadimastem Ltd | -3.04 Million USD | 91.391% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 73.403% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 79.162% |
| BioStem Technologies, Inc. | -7.77 Million USD | 96.635% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -44.214% |
| LadRx Corporation | -3.82 Million USD | 93.155% |
| Cell Source, Inc. | -4.32 Million USD | 93.949% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 61.9% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 61.9% |
| NovAccess Global Inc. | -2.46 Million USD | 89.39% |
| Affymax, Inc. | -15.04 Million USD | 98.26% |
| Itoco Inc. | -919.14 Thousand USD | 71.525% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 93.825% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 76.611% |
| Mobile Lads Corp. | -554.55 Thousand USD | 52.804% |
| CytoDyn Inc. | -18.05 Million USD | 98.551% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -939.833% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -18.924% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 53.654% |
| SYBLEU INC | -149.18 Thousand USD | -75.443% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 85.59% |
| International Stem Cell Corporation | -663 Thousand USD | 60.524% |
| Bioxytran, Inc. | -3.82 Million USD | 93.149% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -397.2% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -1186.755% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 99.278% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 83.824% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 64.431% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 91.587% |
| Neutra Corp. | -229.48 Thousand USD | -14.049% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 98.508% |
| PureTech Health plc | -146.19 Million USD | 99.821% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 98.782% |
| IXICO plc | -1.43 Million USD | 81.787% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 97.242% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.785% |
| CSL Limited | 3.81 Billion USD | 100.007% |
| Cellectis S.A. | -108.85 Million USD | 99.76% |